课题基金 / 基金详情

Out of Time: Biomedicine, Endotoxin Detection, and the Plight of the Horseshoe Crab

Out of Time: Biomedicine, Endotoxin Detection, and the Plight of the Horseshoe Crab
过时的:生物医学、内毒素检测和鲎的困境
批准号:
10577633
负责人:
Kristoffer Whitney
金额:
$4.94万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-06-01 至 2024-05-31

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary This project is to write a book-length account of the biomedical use of American horseshoe crabs (Limulus polyphemus) to produce Limulus Amebocyte Lysate (LAL) – a compound used to detect the presence of potentially deadly toxins in all intravenous drugs, vaccines, and medical devices and a vital part of global public health infrastructure. This monograph will explore the history of LAL, its global implications, and the contemporary biopolitics around crab conservation and synthetic replacements for LAL in the pharmaceutical industry. The book’s contribution to health and medicine will be to shed light on a largely unknown component of public safety, and to aid in the development of theoretical frameworks for understanding the complexities of policymaking around drug and medical device manufacture – particularly when those policies may be in tension with other societal goals, such as environmental protection. No full-length monograph of the LAL industry currently exists, and the proposed book aims to be a contribution and model for cross-disciplinary, humanities-based, and policy-relevant work in analyzing biomedical infrastructures by deepening our understanding of the role of endotoxin detection in public health. More broadly, this project’s approach will lend itself to understanding a wide range of public health issues in which diverse regulatory agencies and stakeholder groups are involved. A significant innovation of this project is to conceptualizes the nexus of human and animal health as a site where biomedicine can both rely upon, and be in tension with, conservation. The proposed book will build upon and contribute to a range of historiography in American medicine, including histories of pharmaceutical development and regulation, as well as global histories of medicine and environmental history. In addition, by collecting published and unpublished documentation and conducting stakeholder interviews, the book will analyze the contemporary regulatory landscape in which LAL, its proposed synthetic replacements, and other biomedical innovations are currently being assessed. This project will appeal to academic scholars, stakeholders, and broad audiences interested in biomedicine and public health.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金